Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558841 | 0.91 | AKR1C3 (0.36) | AKR1C3AKR1C2PLA2G2AHPGDPARP1 | |
| SCHEMBL5558674 | 0.89 | POLB (0.35) | AKR1C3AKR1C2PLA2G2ACNR1CNR2 | |
| SCHEMBL5558566 | 0.89 | PLA2G2A (0.35) | AKR1C3AKR1C2PLA2G2ACNR1CNR2 | |
| SCHEMBL5560567 | 0.89 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGS2 | |
| SCHEMBL5558655 | 0.88 | AKR1C3 (0.36) | AKR1C3AKR1C2HPGDPTGS2 | |
| SCHEMBL5558918 | 0.88 | AKR1C3 (0.35) | AKR1C3AKR1C2PTGS2MEN1KMT2A | |
| SCHEMBL5561824 | 0.87 | AKR1C3 (0.35) | AKR1C3AKR1C2PTGS2 | |
| SCHEMBL5559391 | 0.86 | POLB (0.36) | AKR1C3AKR1C2PLA2G2ACNR1CNR2 | |
| SCHEMBL5559387 | 0.86 | POLB (0.36) | AKR1C3AKR1C2PLA2G2ACNR1CNR2 | |
| SCHEMBL5553774 | 0.84 | AKR1C3 (0.35) | AKR1C3AKR1C2PLA2G2ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006050120-A2 | SYNTHESIS OF COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050032747-A1 | COX-2 and FAAH inhibitors | POLYMER CONCEPTS TECHNOLOGIES PBY, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGS2 | AKR1C3 585/4885AKR1C2 342/4885PLA2G2A 54/4885 |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | AKR1C3 577/4885AKR1C2 563/4885PLA2G2A 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.